House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: A retrospective study

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Chang, Alicia H ^a   Polesky, Andrea ^b,c   Bhatia, Gulshan ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Santa Clara Valley Health & Hospital System   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Adherence; Community health workers; Hepatitis; House calls; Isoniazid; Latent tuberculosis infection; LTBI; Public health nurses; Rifampin

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; CHILD; DRUG ADMINISTRATION; FEMALE; HEALTH AUXILIARY; HUMAN; LATENT TUBERCULOSIS; MALE; NURSE; OUTCOME ASSESSMENT; PATHOLOGY; PATIENT COMPLIANCE; PROFESSIONAL PRACTICE; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CALIFORNIA; CHILD; COMMUNITY HEALTH WORKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOUSE CALLS; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; NURSES, PUBLIC HEALTH; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 84884599556     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-894     Document Type: Article

References (28)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection: American thoracic society. MMWR Recomm Rep 2000 49 RR-6 1 51 15580784
2. Controlled chemoprophylaxis trials in tuberculosis: a general review. Ferebee SH, Bibliotheca tuberculosea 1970 26 28 106 4903501
3. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial: international union against tuberculosis committee on prophylaxis. Bull World Health Organ 1982 60 4 555 564 6754120
4. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Comstock GW, The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 1999 3 10 847 850 (Pubitemid 29488035)
5. Healthy people 2010, vol. two, second edn Washington DC, USA: US Department of Health and Human Services 2000
6. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW, Int J Tuberc Lung Dis 2008 12 11 1235 1254 18926033
7. Latent TB infection treatment acceptance and completion in the United States and Canada. Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, et al. Chest 2010 137 2 401 409 10.1378/chest.09-0394 19793865
8. Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Tulsky JP, Hahn JA, Long HL, Chambers DB, Robertson MJ, Chesney MA, Moss AR, Int J Tuberc Lung Dis 2004 8 83 91 14974750 (Pubitemid 38120710)
9. Development of a pharmacist-managed latent tuberculosis clinic. Last JP, Kozakiewicz JM, Am J Health Syst Pharm 2009 66 17 1522 1523 10.2146/ajhp090034 19710435
10. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E, Arch Intern Med 2002 162 9 1044 1050 10.1001/archinte.162.9.1044 11996616 (Pubitemid 34492535)
11. An official ATS statement: hepatotoxicity of antituberculosis therapy. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al. Am J Respir Crit Care Med 2006 174 8 935 952 10.1164/rccm.200510-1666ST 17021358 (Pubitemid 44564795)
12. What's The relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. Zhang J, Yu KF, JAMA: the journal of the American Medical Association 1998 280 19 1690 1691 10.1001/jama.280.19.1690 (Pubitemid 28532993)
13. Confidence limits made easy: interval estimation using a substitution method. Daly LE, Am J Epidemiol 1998 147 8 783 790 10.1093/oxfordjournals.aje. a009523 9554420 (Pubitemid 28183278)
14. A sharper Bonferroni procedure for multiple tests of significance. Hochberg Y, Biometrika 1988 75 4 800 802 10.1093/biomet/75.4.800
15. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. Rose DN, Schechter CB, Silver AL, JAMA: the journal of the American Medical Association 1986 256 19 2709 2713 10.1001/jama.1986.03380190079029 (Pubitemid 17178087)
16. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in Central Massachusetts. Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS, Clin Infect Dis 2009 49 3 424 427 10.1086/600394 19548835
17. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al. Arch Intern Med 2006 166 17 1863 1870 10.1001/archinte.166.17. 1863 17000943 (Pubitemid 44455169)
18. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Holland DP, Sanders GD, Hamilton CD, Stout JE, Am J Respir Crit Care Med 2009 179 11 1055 1060 10.1164/rccm.200901-0153OC 19299495
19. Recent developments in treatment of latent tuberculosis infection. Menzies D, Al Jahdali H, Al Otaibi B, Indian J Med Res 2011 133 257 266 21441678
20. Three months of rifapentine and isoniazid for latent tuberculosis infection. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al. The New England journal of medicine 2011 365 23 2155 2166 10.1056/NEJMoa1104875 22150035
21. New regimens to prevent tuberculosis in adults with HIV infection. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE, The New England journal of medicine 2011 365 1 11 20 10.1056/NEJMoa1005136 21732833
22. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. Morbidity and mortality weekly report 2011 60 48 1650 1653 22157884
23. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. Holland D, Sanders G, Hamilton C, Stout J, PLoS ONE 2011 6 7 22276 e22276 10.1371/journal.pone.0022276 21789248
24. Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens. Portilla J, Jorda P, Esteban J, Sanchez-Paya J, Merino E, Boix V, Grupo de Estudio Protocolo INH, Enfermedades infecciosas y microbiologia clinica 2003 21 6 293 295 12809583 (Pubitemid 36869936)
25. HIV risk reduction in a nurse case-managed TB and HIV intervention among homeless adults. Schumann A, Nyamathi A, Stein JA, J Health Psychol 2007 12 5 833 843 10.1177/1359105307080618 17855466 (Pubitemid 47339113)
26. Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples. [Article]. Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B, Nurs Res 2008 57 1 33 39 10.1097/01.NNR.0000280660.26879.38 18091290
27. Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. Dobler C, Marks G, PLoS ONE 2012 7 11 48900 e48900 10.1371/journal.pone.0048900 23139824
28. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. Nolan CM, Goldberg SV, Buskin SE, JAMA: the journal of the American Medical Association 1999 281 11 1014 1018 10.1001/jama.281.11.1014 (Pubitemid 29143893)